| 000 | 01775 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250514224036.0 | ||
| 264 | 0 | _c20050829 | |
| 008 | 200508s 0 0 eng d | ||
| 022 | _a1078-0432 | ||
| 024 | 7 |
_a10.1158/1078-0432.CCR-04-2086 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHoppe, Antje | |
| 245 | 0 | 0 |
_aSerum cystatin C is a better marker of topotecan clearance than serum creatinine. _h[electronic resource] |
| 260 |
_bClinical cancer research : an official journal of the American Association for Cancer Research _cApr 2005 |
||
| 300 |
_a3038-44 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 |
_aCreatine _xblood |
| 650 | 0 | 4 | _aCystatin C |
| 650 | 0 | 4 |
_aCystatins _xblood |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aTopotecan _xadministration & dosage |
| 700 | 1 | _aSéronie-Vivien, Sophie | |
| 700 | 1 | _aThomas, Fabienne | |
| 700 | 1 | _aDelord, Jean-Pierre | |
| 700 | 1 | _aMalard, Laurence | |
| 700 | 1 | _aCanal, Pierre | |
| 700 | 1 | _aChatelut, Etienne | |
| 773 | 0 |
_tClinical cancer research : an official journal of the American Association for Cancer Research _gvol. 11 _gno. 8 _gp. 3038-44 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/1078-0432.CCR-04-2086 _zAvailable from publisher's website |
| 999 |
_c15505965 _d15505965 |
||